Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent
Table 1
Patient characteristics.
Melphalan (n=19)
Mitomycin-C (n=29)
p-value
Gender
0.048
Male, n (%)
5 (26)
16 (55)
Female, n (%)
14 (74)
13 (45)
Number of previous surgeries with curative intent
0.99
0 (%)
2 (10)
4 (14)
1 (%)
15 (80)
21 (72)
>1 (%)
2 (10)
4 (14)
Median LN resected from previous surgery, (range)
15 (0-43)
14 (0-145)
0.87
LN metastases at the time of previous surgery, n (%)
12 (71)
18 (67)
1
Adjuvant chemotherapy after previous surgery, n (%)
17 (90)
25 (86)
0.9
Location of tumor origin
0.88
Right, n (%)
6 (32)
8 (28)
Left, n (%)
13 (68)
21 (72)
Peritoneal carcinomatosis occurrence
0.63
Synchronous, n (%)
8 (42)
11 (38)
Metachronous, n (%)
13 (58)
18 (62)
At the time of CRS/HIPEC
NACT (before HIPEC), n (%)
1 (5)
2 (7)
1
Mean age at the time of CRS/HIPEC, years (SD)
52±11
51±9
0.73
Median time from diagnosis to CRS/HIPEC, months (range)
22 (0-82)
16 (0-97)
0.89
Median preoperative PCI (range)
17 (3-35)
13 (3-39)
0.86
PCI≥20, (%)
9 (47)
13 (45)
1
Median LOS, minutes
569
580
0.78
Median LN resected from CRS/HIPEC, n (range)
26 (6-119)
17 (1-53)
0.07
Lymph nodes metastases, n (%)
8 (42)
12 (46)†
0.73
Median length of stay in hospital, days (range)
11 (7-17)
10 (5-59)
0.89
Histopathology
0.98
Well differentiated, n (%)
2 (11)
3 (10)
Moderately differentiated, n (%)
16 (84)
17 (59)
Poorly differentiated, n (%)
1(5)
8 (28)
Not reported, n (%)
0 (0)
1 (3)
NACT: neoadjuvant chemotherapy; LOS: length of surgery; †calculated in 26 patients (not reported in 3 patients).
